Bian, X., Zeng, H., Guo, H., Xing, N., Yang, Y., Xue, B., Zhang, X., Xiao, W., Jiang, J., Sun, T., Chen, W., Wang, Y., Wan, B., He, D., Zhang, Q., Luo, H., Wang, X., Guo, J., Zhao, H., Ye, D. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5047